Clinical and immunological profile of SLE patients: Experience from a Chennai-based tertiary care centre (revisited)

Sham Santhanam1, Madeshwaran M2, Tamilselvam TN3, Rajeswari S4

1Consultant Rheumatologist, Global Hospitals, Chennai, India
2Postgraduate, Department of Rheumatology, Madras Medical College, Chennai, India
3Senior Assistant Professor, Department of Rheumatology, Madras Medical College, Chennai, India
4Professor & HOD, Department Of Rheumatology, Madras Medical College, Chennai, India

Abstract
Aim: To study the clinical and immunological profile of patients with newly detected systemic lupus erythematosus (SLE) presented to a tertiary care centre.

Methods: The study involved patients with newly detected SLE (fulfilling the 1997 revised ACR criteria for SLE), admitted in Madras Medical College and Rajiv Gandhi Government General Hospital Chennai between January 2012 and December 2013.

Results: Hundred patients with SLE were assessed for a period of two years, among them, 59% of the subjects belonged to the 3rd decade of life; 86% of the subjects were females and the remaining were males (M:F ratio 6:1). Fever (81%) was the commonest initial manifestation reported, followed by arthritis (61%), cutaneous (58%), neuropsychiatric (45%), and renal (44%) manifestations. In patients with lupus nephritis, class IV (38.63%) was common, followed by class III (22.72%) and class V (15.9%). ANA was positive in all patients (100%), anti-Smith (Sm) was found in 49% of the subjects, followed by anti-Ro (47%), anti-ds DNA (45%), anti U1 RNP (42%) and reduced complements in 72%.

Conclusion: SLE was more common among young females in their 3rd decade. In our study, patients had more of constitutional symptoms followed by joint and skin manifestations. High disease activity was noted in 84% of the patients. The incidence of neuropsychiatric and cardiovascular manifestations was more compared to other Indian studies.

Keywords: SLE, systemic lupus erythematosus, neuropsychiatry, renal, clinicoepidemiological, immunological

Introduction
SLE is the typical autoimmune disease with varied clinical manifestations involving multiple organs. Inadequate data on clinicoepidemiological manifestations and lack of disease registries from India pose major barrier to further understand patient/disease characteristics and to build a comprehensive knowledge base on SLE. In contrast to the Chennai-based study conducted in 1983, our recent study has indicated an increase in neuropsychiatric manifestations of SLE. In view of these findings, the present study has focused on re-evaluating the clinical and immunological features of patients presenting with SLE to our centre.

Materials and methodology
The cross-sectional study was conducted on 100 newly detected SLE patients admitted in Department of Rheumatology, Madras Medical College & Rajiv Gandhi Government General Hospital, Chennai. The duration of study was from January 2012 to December 2013. The ethical committee approval and informed consent in patients own language were obtained before starting the study.

All the patients who satisfied the 1997 revised ACR classification criteria for SLE were chosen, detailed history was obtained and complete clinical examination
was performed. Patients were subjected to baseline blood investigations, immunological investigations, and relevant radiological investigations. ANA was done by either ELISA or indirect immunofluorescence (IIF) by Hep-2 method, dsDNA, antcardiolipin antibody by ELISA, and complements by nephelometry. ANA profile 3 was done by EUROIMMUN Line Immunoassay (Immunoiblot). Patient’s generalized disease activity was calculated using SLE Disease Activity Index (SLEDAI). Patients with features of overlap syndrome were excluded from the study.

Results and analysis
The study group had 59% of the patients (48% females and 11% males) in the age group of 21-30 years and 24% (22% females and 2% males) belonging to the age group of 17-20 years. So the maximum number of patients was from 2nd and 3rd decades. Among the subjects, 86% of the patients were females and 14% were males. Around 81% of the subjects had fever and constitutional symptoms followed by arthritis, and cutaneous, neuropsychiatry and renal involvement (Fig. 1). Seizure was the common neuropsychiatric manifestations observed, followed by psychosis, stroke etc. (Table 1). In our study group, class IV lupus nephritis was common, followed by class III and class V (Table 2). ANA was positive in 100%, ds DNA in 45%, and low complements in 73%. Anti-Sm was found

![Fig. 1: Clinical features of SLE noted in the study cohort (%)](image)

| Neuropsychiatric manifestations | No. of patients |
|---------------------------------|-----------------|
| Seizures                        | 25              |
| Psychosis                       | 19              |
| Stroke                          | 10              |
| Headache                        | 7               |
| Peripheral neuropathy           | 6               |
| Transverse myelitis             | 2               |
| Cognitive dysfunction           | 2               |
| Retinal vasculitis              | 1               |

Table 1: Distribution of neuropsychiatric manifestations in the study cohort
in 49%, followed by anti Ro, anti-dsDNA, and anti-U1RNP (Fig. 2). High disease activity was noted in 84% of the patients.

Out of 100 patients, 25 had flare, of which 16 (64%) had mild/moderate flare and 9 (36%) had severe flare. Among the study participants, 42 had acute cutaneous lesions, 26 had sub-acute cutaneous lesions, and 13 had chronic cutaneous lesions.

**Discussion**

In the present study, the majority of patients were in their 2nd and 3rd decades with a mean age of 25.45 years. The female to male ratio in our study was 6:1. The corresponding female to male ratios noted in Indian studies by Renu et al., Binoy et al., and Malaviya et al. were 11:1, 19:1 and 8:1.2-4 The average disease duration noted in the present study was 1.63 year, which is comparable to the study done by Saigal et al. (2 years) and Malaviya et al. (17 months).2-4 The mean age of onset of disease in the current study was 25.45 years and the median age of onset noted in studies by Saigal et al. and Binoy et al. was 27.9 and 21.6 years respectively.2,3 Other Indian studies by Malaviya et al. and Vaidya et al. have reported a median age of onset of 24 and 26 years. So the median age of onset was found to be similar in all the Indian studies.4,5 Comparison of the current study with previous study done at the same centre has reported an increased prevalence of neuropsychiatric manifestations, leucopenia, thrombocytopenia, cardiovascular and constitutional symptoms. Comparison

---

![Chart: Prevalence of autoantibodies noted in SLE cohort (%)](chart.png)

**Table 2: Incidence of lupus nephritis in the study group as per the ISN/RPS 2003 classification**

| Class | No. of patients | %  |
|-------|----------------|----|
| I     | 2              | 4.54 |
| II    | 3              | 6.81 |
| III   | 10             | 22.72 |
| IV    | 17             | 38.63 |
| V     | 7              | 15.9 |
| VI    | 1              | 2.27 |
| III + V | 1              | 2.27 |
| IV + V | 2              | 4.54 |
| V + VI | 1              | 2.27 |
of the clinical features reported in the present study with other Indian studies is given in Table 3.

### Conclusion

The present study has reported higher prevalence of constitutional symptoms, followed by joint and skin manifestations. Around 84% of the patients demonstrated high disease activity. The incidence of renal and neuropsychiatric manifestations was similar, but the rate of incidence of neuropsychiatric and cardiovascular manifestations was more compared to other Indian studies.

| Clinical features      | Present study (n=100) 2014, S.India (Chennai) (%) | Malaviya et al. (n=101) 1985, N.India (%) | Madhavan et al. (n=54) 1983, Madras (%) | Binoy et al. (n=75) 2003 S.India, N.Kerala (%) | Vaidya et al. (n=220) 1997 W.India (%) | Renu Saigal et al. (n=60) 2011 W.India (%) |
|------------------------|-------------------------------------------------|------------------------------------------|------------------------------------------|---------------------------------------------|------------------------------------------|--------------------------------------------|
| Fever                  | 81                                             | 44                                       | 11.1                                     | 4.0                                         | NA*                                      | 6.7                                       |
| Lymphadenopathy        | 33                                             | NA*                                      | NA*                                      | NA*                                         | NA*                                      | NA*                                       |
| Hepatomegaly/Splenomegaly | 39                                           | NA*                                      | NA*                                      | NA*                                         | NA*                                      | NA*                                       |
| Weight loss            | 11                                             | NA*                                      | NA*                                      | NA*                                         | NA*                                      | NA*                                       |
| Arthritis              | 61                                             | 66                                       | 81.4                                     | 89.3                                        | 70.91                                    | 86.7                                      |
| Myositis               | 41                                             | NA*                                      | NA*                                      | NA*                                         | NA*                                      | NA*                                       |
| Cutaneous              | 58                                             | 85                                       | 62.9                                     | 64                                          | NA*                                      | NA*                                       |
| Cardiovascular         | 29                                             | 5                                        | 9.2                                      | 5.3                                         | 11.8                                     | 6.7                                       |
| Pulmonary              | 11                                             | 17                                       | 16.6                                     | 8                                           | 15.5                                     | 11.7                                      |
| Renal                  | 44                                             | 73                                       | 38.8                                     | 33.3                                        | 35                                       | 56.7                                      |
| Neuropsychiatry        | 45                                             | 15                                       | 20.3                                     | 13.3                                        | 25.5                                     | 13.3                                      |
| Hemolytic anemia       | 29                                             | NA*                                      | NA*                                      | 0.01                                        | NA*                                      | 25                                        |
| Leukopenia             | 26                                             | 16                                       | 3.7                                      | 14.7                                        | NA*                                      | 43.3                                      |
| Thrombocytopenia       | 39                                             | 11                                       | 7.4                                      | 12                                           | NA*                                      | 33.3                                      |
| Serositis              | 32                                             | NA*                                      | NA*                                      | NA*                                         | NA*                                      | NA*                                       |
| Raynaud’s              | 7                                              | 32                                       | 1.8                                      | 2.7                                          | 15.5                                     | 21.                                       |
| ANA                    | 100%                                           | 98%                                      | NA*                                      | 93.3%                                       | NA*                                      | 98.3%                                     |
| ds DNA                 | 45%                                            | 55%                                      | NA*                                      | 76%                                         | NA*                                      | 65%                                       |
| Complements            | 72%                                            | NA*                                      | NA*                                      | NA*                                         | NA*                                      | NA*                                       |

*Not available

### Competing interests

The authors declare that they have no competing interests.

### Citation

Santhanam S, Madeshwaran M, Tamilselvam TN, Rajeswari S. Clinical and immunological profile of SLE patients: Experience from a Chennai-based tertiary care centre (revisited). IJRCI. 2016;4(1):OA1.

**Submitted:** 21 April 2015, **Accepted:** 7 July 2015, **Published:** 8 January 2016

Correspondence: Consultant Rheumatologist, Global Hospitals, Chennai, India
itsdrsham@gmail.com

### References

1. Madhavan R. SLE – The Madras Experience. J Assoc Phys India
2. Saigal R, Kansal A, Mittal M, Singh Y, Maharia HR, Juneja M. Clinical profile of systemic lupus erythematosus patients at a tertiary care centre in Western India. J Indian Acad Clin Med. 2011;13:27–32.
3. Paul BJ, Fassaludeen M, Nandakumar, Razia MV. Clinical profile of Systemic Lupus Erythematosus in Northern Kerala. J Indian Rheumatol Assoc 2003; 11: 94-7.
4. Malaviya AN, Singh RR, Kumar A, De A, Kumar A, Aradhye S. SLE in Northern India. A review of 329 cases. J Assoc Phys India 1988; 36: 476-80.
5. Vaidya S, Samant RS, Nadkar MY, Borges NE. SLE- review of two hundred and twenty patients. JIRA 1997; 5: 14-8.